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This study evaluated a smartphone application (“app”) aimed at improving treatment adherence and cardiovascular lifestyle in
MI patients.
Design Multicenter, randomized trial.
Methods A total of 174 ticagrelor-treated MI patients were randomized to either an interactive patient support tool
(active group) or a simplified tool (control group) in addition to usual post-MI care. Primary end point was a composite
nonadherence score measuring patient-registered ticagrelor adherence, defined as a combination of adherence failure events
(2 missed doses registered in 7-day cycles) and treatment gaps (4 consecutive missed doses). Secondary end points included
change in cardiovascular risk factors, quality of life (European Quality of Life–5 Dimensions), and patient device satisfaction
(System Usability Scale).
Results Patient mean age was 58 years, 81% were men, and 21% were current smokers. At 6 months, greater patient-
registered drug adherence was achieved in the active vs the control group (nonadherence score: 16.6 vs 22.8 [P = .025]).
Numerically, the active group was associated with higher degree of smoking cessation, increased physical activity, and
change in quality of life; however, this did not reach statistical significance. Patient satisfaction was significantly higher in the
active vs the control group (system usability score: 87.3 vs 78.1 [P = .001]).
Conclusions In MI patients, use of an interactive patient support tool improved patient self-reported drug adherence and
may be associated with a trend toward improved cardiovascular lifestyle changes and quality of life. Use of a disease-specific
interactive patient support tool may be an appreciated, simple, and promising complement to standard secondary prevention.
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hCardiovascular disease is the single most common
cause of death and is often preventable. In patients with
myocardial infarction (MI), secondary prevention mea-
sures, pharmacologic, and behavior-oriented are essential
to reduce morbidity and mortality.1
Education concerning the benefits of adherence to
prescribed medical treatments and lifestyle modification
is a central component in reducing risk of recurrent
events and improving quality of life (QoL).2,3 As medical
and technological advances in the treatment of MI
over the years have shortened hospital stays and
thereby reduced patient contact and opportunities for
education,4 patient participation in cardiac rehabilitation
(CR) programs serves an important purpose and has
proven to reduce risks. However, the underuse and
ineffectiveness of these programs are a matter of concern.
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coronary artery disease (SWEDEHEART), only 16% of MI
patients reached all predefined targets for secondary
prevention 1 year after MI.5 The reasons for ineffective-
ness of CR programs are multifactorial, but likely include
a lack of patient recognition on the benefits of lifestyle
modification and motivation. Poor adherence to cardiac
medication is a cardinal problem in reaching secondary
preventive targets and has been associated with increased
risk of CV morbidity and mortality.6,7 Premature discon-
tinuation of dual antiplatelet treatment (DAPT) is
especially risky given the often fatal consequence of
stent thrombosis.2,8 Some of the main reasons for patient
nonadherence to their medication include lack of
understanding of the disease and mechanisms of drug
action, or simple forgetfulness.9–15
New initiatives are urgently needed to improve the
effectiveness of secondary prevention programs. eHealth
solutions (electronic communication and health informa-
tion technology in health care practice) have been shown
to improve self-management, adherence to lifestyle
modification, and medical therapy.6,7,16 Thus, eHealth
solutions may have the potential to decrease the risk of
recurrent events and improve QoL. In this randomized
study of an eHealth solution, we assessed the hypothesis
that the use of an interactive patient support tool would
improve adherence to antiplatelet treatment and achieve-
ment of secondary prevention targets in patients with a
recent MI.Methods
Study design
The SUPPORT study (A study to evaluate the use of
mobile-phone based patient support in patients diag-
nosed with MI) was a randomized, multicenter study
evaluating the impact of an interventional medical device
(ie, smartphone-based interactive patient support tool)
on drug adherence and lifestyle changes in subjects
diagnosed as having MI and treated with the platelet
inhibitor ticagrelor. Patients were recruited from 16
cardiology departments in Sweden, and the study
intervention was added to traditional secondary preven-
tive care, including CR programs. Secondary preventive
care in Sweden is very much standardized. All patients
younger than 75 years receive at least 2 post–hospital
discharge visits at the clinic; at 2 weeks to a trained nurse
and after 6 to 8 weeks to a physician. In uncomplicated
cases, the patient is thereafter referred to primary care for
follow-up. Also, all patients receive a recommendation,
together with family members, to participate in educa-
tional and physical training programs. Participation is not
logged because these programs are optional.
The requirements for study inclusion were women or
men older than 18 years, diagnosed as having an
ST-elevation myocardial infarction or a non–ST-elevationmyocardial infarction with treatment-initiated in-hospital
and prior to randomization with ticagrelor 90 mg twice
daily and for the duration of 1 year according to guideline
recommendations. Additional requirements included
having daily access and knowledge how to handle a
personal smartphone, Swedish language skills, and
willingness and ability to participate in scheduled
follow-up visits. Patients were excluded if they already
were participating in any interventional clinical trial or
device study; were on treatment with triple antithrom-
botic treatment or anticoagulation; had planned surgical
interventions; had limited life expectancy (b12 months);
were pregnant; or, at the investigator's discretion, were
judged unsuitable for participation, for example, due to
inability to follow a structured physical activity program.
Prior to discharge and after oral and written informed
consent, patients were randomized to either an active or
a control group. The active group received a complete
interactive patient support tool (Web-based application
[app]) installed on their own smartphones containing an
extended drug adherence e-diary and secondary preven-
tion educational modules (Figure 1). The control group
received a simplified tool containing only a simplified
drug adherence e-diary without the secondary prevention
educational modules installed on their own smartphones.
Patients were educated by study personnel on how to use
the drug adherence e-diary (active and control group) and
the interactive patient support tool (active group). After
visit 3, the tools for both groups were uninstalled.
Both patient groups had access to a drug adherence
e-diary on their smartphones to register their daily
ticagrelor intake. Recall registration of drug intake, for
one or both doses, was only possible within a 48-hour
span. The evening dose could not be registered before 3
PM in order to prevent preregistrations. If the patient did
not make a registration for a day, the app handled this as
missed doses for that day. In case of missed drug
registrations (morning and evening dose) during 1 day,
both patient groups received a short message service
(SMS) the following day encouraging patients to report
their ticagrelor use. In addition to SMS reminders, the
active group also received educational messages within
the tool according to their reported registrations.
All device-related adverse effects and device deficien-
cies were registered during the study. The study was
performed according to good clinical practice. The study
protocol was reviewed and approved by the regional
ethics committee in Uppsala, Sweden (reference number
2013/192), and registered at ClinicalTrials.gov (clinical
trial identifier: NCT01874262).
The interactive patient support tool
The educational modules in the complete interactive
patient support tool (available to the active group only)
included 4 main modules: extended drug adherence
e-diary, exercise, weight, and smoking modules
Figure 1
The complete interactive patient support tool (app), covering the start page, e-diary, exercise module, BMI module, and blood pressure module
(from left to right).
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register information in these 4 modules. In addition,
patients in the active group could also register data
regarding their blood pressure, low-density lipoprotein
cholesterol, and blood glucose levels in the interactive
patient support tool. All modules included referenced
medical information.
The tool had a unique message structure with a couple
of hundred feedback and information messages, aimed to
create a personalized and nonstatic approach. The
automatized feedback message logic was developed to
give the patients relevant and individualized feedback
based on their progress and status. There were 2 types of
feedback messages; “status-based” messages and “infor-
mation” messages. The status-based messages were
configured to describe or give feedback on the patient's
status according to the traffic light model. In the
adherence module, depending on the number of missed
doses the last week the patient's color status for
adherence would be “green,” “yellow,” or “red.” For
each color status, there were 15 different but similar
predefined messages in the drug adherence e-diary
module in order to give a variety and sense of
individualization. For example, the “green” status yielded
a short confirmation message that the patient performed
well, whereas a “red” status prompted a brief motiva-
tional and supportive message that the patient could do
better. When messages were generated, the patient also
received an SMS notification.
Data entered by the patient were not monitored. In
addition to the 4 main modules, the smartphone-based
interactive patient support tool also provided general
information regarding the cause, symptoms, and treat-
ment of MI to patients in the active group.Follow-up visits
After randomization, all patients were evaluated at
baseline and at 2 study visits during the 6-month study
period. The second study visit took place 6 to 10 weeks
after discharge. The third visit (study end) was scheduled
6 months after randomization. All patients completed the
European Quality of Life–5 Dimensions Visual Analogue
Scale (EQ-5D VAS) and the Physical Activity question-
naires during all 3 visits, whereas the Medication
Adherence Rating Scale (MARS-5), a self-report question-
naire, was completed at the second and third visits to
determine nonadherence and type of nonadherence
behavior.17,18 Patients were also encouraged to bring all
their unused ticagrelor tablets and empty blisters and
packages to every study visit for a manual pill count.
Self-reported device usability was assessed for all patients
(using the System Usability Scale [SUS]) at the second and
third visits, respectively.19 The SUS was developed by
Brook20 and uses 10 questions to measure the subjective
system satisfaction using a response scale from 1 to 5. In
addition, patients in the active group were simultaneous-
ly asked to rate their satisfaction with the interactive
patient support tool (online Supplementary Figure S2-1).Primary objective and study end points
The primary objective was to assess treatment adher-
ence to ticagrelor by a composite end point of adherence
failure events and treatment gaps in MI patients using the
smartphone-based interactive patient support tool com-
pared with patients using the simplified tool (e-diary
only). Adherence failure events and treatment gaps were
identified based on the information the patient entered
into the drug adherence e-diary.
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consequences of poor adherence was taken into
account when designing the study's definition of
“drug adherence,” Because suboptimal plasma levels
of ticagrelor might lead to acute thrombotic events in
this population, we a priori designed a definition
where treatment gaps were weighted greater than
adherence failures. The primary composite end point
was defined as a nonadherence score based on the
combination of adherence failure events and treat-
ment gaps. Adherence failure events were defined as
2 missed doses during an observation cycle of up to 7
days. The first registered missed dose of ticagrelor in
the e-diary initiated an observation cycle of 1 week. If
a second missed dose was registered during the
week, this was considered an adherence failure
event. The third missed dose initiated a new
observation cycle, and the process restarted. If the
second missed dose was registered after more than 1
week, this was not defined as an adherence failure
event, but initiated a new observation cycle. Treat-
ment gaps were defined as patient reported gaps of 4
consecutive doses.
The secondary objectives of the study were to evaluate
the impact of the smartphone-based interactive patient
support tool on CV risk factors such as body mass index
(BMI), level of physical activity, and smoking cessation.
Furthermore, analyses of QoL, patient drug use (pill count
and MARS-5), patient use of the smartphone-based
interactive patient support tool over time, system
usability and patient satisfaction, and safety of the
smartphone-based interactive patient support tool were
included.
Statistical methods
All randomized patients with no protocol violations
were included in the full analysis set (FAS). There were
8 patients with protocol violations, either incorrectly
randomized or having a too old smartphone device
preventing successful installation of the interactive
patient support tool or the simplified tool. The
evaluable analysis set constituted all patients from the
FAS with at least 1 month's follow-up time (Figure 2).
The evaluable analysis set formed the basis for the
primary end point analysis. The composite end point
was calculated as the sum of adherence failure events
and treatment gaps, where the number of treatment
gaps was weighted equal to 4 missed doses to reflect
that a long treatment gap was judged as more medically
severe than a short, single-tablet miss. Missed doses
were counted as part of either a treatment gap or an
adherence failure event. The total number of adherence
failure events and treatment gaps during the study
participation (from randomization to study termina-
tion) was derived, and the composite end point was
evaluated at visit 2 and visit 3.Documented patient-reported technical or similar
problems with e-diary registration resulted in registra-
tions being censored from the patient registered drug
adherence analyses. For 1 patient in each treatment
group, this led to censoring of the entire e-diary.
The percentile rank of the composite end point was
calculated for all subjects at the end of the study. For
subjects prematurely ending the study, the percentile
rank was calculated at the last dose. Hence, when a
subject left the study, the composite score for that subject
was compared with all other subjects after an equivalent
follow-up period and assigned a percentile rank, which
was used when evaluating the primary end point, by
means of a Mann-Whitney test. Time to first nonadher-
ence event was also illustrated using Kaplan-Meier curves.
As part of the secondary analyses, the number of
adherence events and the number of treatment gaps were
compared separately between the study groups using the
same methods as in the analysis of the primary end point.
Furthermore, the proportions of subjects experiencing
either an adherence failure event or treatment gap were
compared on a monthly basis using a χ2 test. The
proportions of subjects with a treatment gap of at least 14
days were compared between the study groups using a
χ2 test, and the difference in time up to the first such
event was analyzed by Cox regression. Absolute values
and changes in CV risk factors, physical activity, smoking
cessation, EQ-5D, MARS-5, and SUS score at visits 2 and 3
were analyzed using the Mann-Whitney test based on the
FAS population.
We calculated a sample size of 74 in each group to have
80% power to detect a difference in means of 0.7 events
between the 2 groups, assuming that the common
standard deviation is 1.5 using a 2-group t test with a
.050 two-sided significance level. To compensate for
potential dropout during the study period, a total of 80
patients in each group would be randomized. This
assumption was equivalent to a decrease of 19% in the
number of nonadherent events in the group with the
better adherence.
Use of the e-diary in the 2 study groups was compared
by Cox regression and the proportions of subjects who
stopped using the e-diary by a χ2 test.
Funding
The SUPPORT study was supported by AstraZeneca.
Results
Study population and background characteristics
In total, 174 patients (91 in the active group and 83 in
the control group) were randomized. Because of protocol
violations in 8 patients (5 in the active group and 3 in the
control group), 166 patients were evaluable and included
in the FAS population (Figure 2). The 8 patients with
protocol violations were either incorrectly randomized or
Figure 2
Patient flowchart.
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installation of the interactive patient support tool or the
simplified tool. Four patients had less than 1-month
follow-up and were excluded from the evaluable analyses
set, consisting of 162 patients.
Mean patient age was 58 years, 81% were men, mean
BMI was 29 kg/m2, 13% had diabetes, and 21% of the
patients were current smokers (Table I). None of the
baseline characteristics were significantly different be-
tween study groups.
Patient self-reported drug adherence in e-diary
At study end, the mean nonadherence score was
significantly lower in the active group compared with
the control group (16.6 vs 22.8, P = .025) (Figure 3). The
proportion of patients who prematurely stopped using
the e-diary was low and did not differ between the 2 study
groups (online Supplementary Figure S2-2).Lifestyle modifications and QoL
No significant changes regarding lifestyle modifications
were seen between the study groups. Nonetheless, the
active group showed positive trends for smoking
cessation (number of quitters among active smokers: 16
vs 5, P = .139), increased physical activity (median
change in exercise minutes per week: +90 vs +65, P =
.612), and increased QoL (change in EQ-5D VAS: 14.7 vs
8.4, P = .059) from baseline to end-of-study visit
compared with the control group (Table II).
System usability score and patient satisfaction
There was no difference in e-diary discontinuation in
the active group compared with the control group
(online Supplementary Figure S2-2). The system usability
score was higher in the active group compared with the
control group, respectively, both at the second visit and
at study end (end of study: 87.3 vs 78.1, P = .001) (Table





Men, n (%) 71 (82.6) 63 (78.8)
Age, mean (y) 56.8 (8.0) 58.4 (8.6)
Smokers, n (%) 22 (25.6) 12 (15.0)
Former smokers, n (%) 29 (33.7) 32 (40.0)
Height, mean (cm) 177.4 (8.2) 176.4 (8.1)
Weight, mean (kg) 91.4 (22.0) 88.5 (16.2)
BMI, mean (kg/m2) 28.9 (5.6) 28.4 (4.7)
Normal weight (b25 kg/m2), n (%) 21 (24.4) 21 (26.3)
Overweight (25-30 kg/m2), n (%) 33 (38.4) 31 (38.8)
Obese (N30 kg/m2), n (%) 32 (37.2) 28 (35.0)
LDL cholesterol, mean (mmol/L) 3.9 (1.2) 3.3 (0.9)
Systolic blood pressure, mean (mm Hg) 131.1 (14.6) 125.2 (17.9)
Diastolic blood pressure, mean (mm Hg) 78.8 (11.0) 75.5 (11.0)
Prior MI, n (%) 6 (7.0) 8 (10.0)
Prior PCI, n (%) 7 (8.1) 9 (11.3)
Prior CABG, n (%) – 1 (1.3)
Angina pectoris, n (%) 1 (1.2) 3 (3.8)
Heart failure, n (%) – –
Atrial fibrillation, n (%) – 2 (2.5)
Embolic stroke, n (%) 1 (1.2) 1 (1.3)
Peripheral artery disease, n (%) 1 (1.2) –
Chronic kidney disease, n (%) 1 (1.2) 2 (2.5)
COPD, n (%) – 2 (2.5)
Asthma, n (%) 4 (4.7) 4 (5.0)
Diabetes, n (%) 8 (9.3) 13 (16.3)
Hypertension, n (%) 40 (46.5) 38 (47.5)
Dyslipidemia, n (%) 24 (27.9) 13 (16.3)
Abbreviations: CABG, Coronary artery bypass grafting; COPD, chronic obstructive
pulmonary disease; LDL, low-density lipoprotein; n, number.
SDs are given within parentheses if not stated otherwise.
Figure 3
omposite primary end point of adherence failure and treatment
aps. n, number.
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questionnaire (online Supplementary Figure S2-1)
showed that 97.5% of the patients in the active group at
study end would recommend the tool to other patients in
the same situation. In addition, 68.4% of patients reported
willingness to continue using the interactive patient
support tool. More than 80% of the patients found that
the interactive patient support tool gave relevant
information about their disease and increased their
insight and motivation to pursue a healthier lifestyle.
Voluntary comments were also collected, seemingly
reflecting the overall results from the interactive patient
support tool satisfaction questionnaire (online Supple-
mentary Figure S2-3).
No adverse device effects were reported during the
study, thus indicating no safety concerns with the
interactive patient support tool.
Medication adherence rating scale
There was no difference in self-reported adherence
measured by MARS-5 at the end-of-study visit, when the
mean value was close to the highest possible score of
25 (24.4 in the active group and 24.5 in the control group,
P = not significant). Only a limited number of patientsC
gparticipated in pill count, and pill count results are
therefore not reported.Discussion
Smartphone apps have the potential to address the
complexity of nonadherence behaviors regarding both
medical treatment and lifestyle modifications. In this
study, we show that the use of a smartphone-based
interactive patient support tool not only improved
patient self-reported drug adherence, but also may be
associated with a trend toward improved cardiovascular
lifestyle changes and QoL in patients after an MI.
A unique aspect of our interactive patient support tool
is the feature for drug adherence, which was the primary
outcome measured, nonadherence score. The nonadher-
ence score is a binary event describing 2 drug use failure
qualities (adherence failure and treatment gaps), impor-
tant when assessing drugs with short half-life and with
potential life-threatening consequences of missed doses.
Not only the quality but also the quantity of drug use
failures over time is important when assessing the
accumulated risk burden, and this is also reflected in
the nonadherence score.
In MI patients, it is well known that both short- and
long-term adherence to secondary preventive medica-
tions is poor. Premature discontinuation of DAPT is the
single most important predictor of stent thrombosis,
often presenting as sudden death.21 In the PARIS registry,
57% of patients who had undergone percutaneous
coronary intervention (PCI) had, at 2 years' follow-up,
stopped taking DAPT, irrespective of reason.2 It is not
uncommon that MI patients treated with PCI often feel
Table II. Secondary objectives and changes from baseline to study end (visit 3)
Active group Control group Total P
Clinical outcome
Smoking, n (%) 22 (25.6) 12 (15.0) 34 (20.5) .135
Quitters, n (%) 16 (−80.0) 5 (−45.5) 21 (−67.7) .139
n 81 72 153
BMI, kg/m2, mean, (SD) 28.9 (5.6) 28.4 (4.7) 28.7 (5.2) .698
BMI change (kg/m2), mean (%) −0.6 (−2) −0.5 (−2) −0.6 (−2) .366
n 80 72 152
LDL cholesterol (mmol/L), mean (SD) 3.9 (1.2) 3.3 (0.9) 3.6 (1.1) .011
LDL cholesterol change (mmol/L), mean (%) −1.8 (−44) −1.0 (−26) −1.5 (−36) .004
n 34 30 64
SBP (mm Hg), mean (SD) 131.1 (14.6) 125.2 (17.9) 128.2 (16.5) .015
SBP change (mm Hg), mean (SD) (%) −0.6 (−0.3) −1.1 (−0.4) −0.9 (−0.3) .749
n 80 72 152
Exercise
No. of physical activity sessions per week (SD) 3.5 (2.6) 3.5 (2.6) 3.5 (2.6) .867
Change (median), sessions per week (%) +1.5 +1.0 +1.0 .770
n 80 71 151
Exercise minutes per week (SD) 181.2 (209.8) 201.1 (198.8) 190.8 (204.2) .527
Change (median), minutes per week (%) +65.0 +75.0 .612
n 80 71 151
Exercise N150 min/wk 46.5% 51.3% 48.8% .649
Change, exercise N 150 min/wk (%) +33.8% +21.1% +27.8%
n 80 71 151
QoL (EQ-5D VAS)
Baseline 67.8 (19.3) 69.1 (19.5) 68.4 (19.3) .622
End of study 82.7 (11.6) 78.2 (15.3) 80.6 (13.6) .090
Change, VAS score (%) +14.7 (+38) +8.4 (+21) +11.7 (+30.0) .059
n 80 71 151
Abbreviations: LDL, Low-density lipoprotein; n, number; SBP, systolic blood pressure.
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have been cured after stenting. This may contribute to a
lack of perceived necessity to continue with DAPT.14
Reasons for the increased drug adherence in the active
group may be due to a combination of the additional
features, such as reminders and educational modules.22–24
In our study of 174 patients during a 6-month period after
an MI, we were able to detect a significant difference in
patient self-reported nonadherence score and treatment
gaps between the 2 groups in favor of the interactive
patient support tool, despite a high ticagrelor adherence
in both study groups. The positive effect of patient
support in our study is consistent with that in other
studies on antiplatelet drug treatments, in prospective
randomized settings.24,25
Only one prior randomized clinical trial in MI patients
has evaluated the use of a smartphone application in
patients post-MI.16 In this study by Varnfield et al,16 120
patients with MI were randomized to usual care post-MI
or use of a smartphone, which included monitoring
of health and physical activity and provided
motivational and educational materials and feedback via
text messages. The primary outcome in this study was
uptake, adherence, and completion of a CR program.
Secondary outcomes were change in modifiable lifestyle
factors, biomedical parameters, and QoL assessed atbaseline and after 6 weeks. Results from this study were
positive; patients randomized to use of the smartphone
app had higher adherence rates and improved
equally well compared with patients participating in
usual care regarding CV risk factor profiles and QoL.
Despite differences compared with our study, as well
as weaknesses in study design,26 Varnfield and
colleagues' conceptual findings lend important
support to our results, which, in turn, add additional
scientific evidence for the positive effect of use of
smartphone apps in secondary prevention management
in MI patients in addition to standard secondary
prevention.
In our study, the primary outcome was chosen to
detect ticagrelor treatment errors defined as occurrence
of adherence failure and treatment gaps. Because there is
no golden standard to measure adherence,27 we chose to
validate the primary outcome measure with 2 different
established adherence measurement methods: MARS-5
and pill count. Neither MARS-5 nor pill-count detected
significant differences in adherence. The inability of the
MARS-5 questionnaire to detect differences could be
explained by the design of the questionnaire (focused
more on the general impact of pharmacologic therapy
and the attitude to medication) and self-reported recall
bias.27,28
Table III. Self-reported device usability score assessed for all





Score at visit 2,
mean (SD)
87.2 (15.0) 81.1 (16.2) 84.3 (15.8) .002
n 85 76 161
Score at study end,
mean (SD)
87.3 (13.9) 78.1 (18.9) 83.0 (17.0) .001
n 80 71 151
Abbreviation: n, number.
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adherence, the method has several limitations. In this
study, patients were not providedwith ticagrelor as a study
drug. Hence, patients were not dependent on study
investigators for prescription refills. This may be a
contributing factor to the low proportion of patients
participating in the manual pill count, which is the main
reason for the use of the patient-reported adherence
measure in evaluating our primary outcome. A robust use
of the e-diary in both treatment groups over time supports
this decision (online Supplementary Figure S2-2).
Although the present study was not powered to
demonstrate differences in secondary end points, we
observed a positive trend for the number of patients who
stopped smoking and increased their level of physical
activity when using the interactive patient support tool
compared with the control group. One of the limitations
of present CR programs is the lack of patient involvement
and health care resources to provide constant support
and feedback in implementing lifestyle changes.
Although secondary prevention is a lifelong endeavor,
the window of opportunity is often larger during
hospitalization and in the early postdischarge phase.
Because the interactive patient support tool encourages
self-registration of important variables related to CV
health and provides visual feedback on changes, patient
engagement is augmented. Quality of life also improved
to a greater extent in the active group, which often can
be associated with better physical and mental well-being.
This, in turn, may increase and motivate adherence to
secondary preventive treatment recommendations.29,30
There was no difference in device use time between the
study groups. This may well have to do with the fact that
this was a study setting in which patients who were
included were willing to continue registration for the
duration of the study. However, the satisfaction in use of
the device was higher in patients using the interactive
patient support tool comparedwith those using the e-diary,
suggesting that the additional components were of
incremental value to the patient. Specifically, more than
80% of the patients found that the interactive patient
support tool gave relevant disease information, increased
insight into their health situation, increased motivation toimprove their health situation, and provided more
opportunities to improve their health status. Most patients
in the active group stated that they would like to continue
to use the interactive patient support tool if possible and
would recommend the tool to other patients.
Despite protocol-driven activities, with drug regis-
tration and focus on secondary prevention in both
groups, the study showed significant effects on ticagrelor
adherence and trends in improved cardiovascular
lifestyle and QoL with the smartphone-based interactive
patient support tool. Thus, we suggest that effect on
adherence, cardiovascular lifestyle, and QoL is probably
underestimated in this study setting compared with real
clinical setting.
Limitations
Despite being a randomized trial, this study has several
limitations that should be taken into consideration.
Because of the nature of the study, it was impossible to
blind the intervention to both observer and patient. The
absence of observer blinding might therefore have
introduced a confounding effect on the result. The
number of pill counts was limited in the study, and an
objective validation of the self-registered drug use was
not possible. The limited pill counts made correlation
between e-diary registration and actual missed dose
impossible to assess. However, we found a similarly
high e-Diary compliance level in both groups (online
Supplementary Figure S2-2), which increases the likeli-
hood of conscious registration of missed doses in both
groups. The study was not powered to show differences
in the secondary end points, and an overall high quality of
secondary prevention care in Sweden limited the
probability to show significant effect on lifestyle changes.
Nevertheless, both smoking cessation and level of
physical activity trended in a positive direction for the
smartphone-based interactive patient support tool. Fur-
thermore, patient education programs may have an
overall effect on adherence, albeit the direction a
potential confounding effect would take is not known.
Finally, the prerequisite of the patients included in the
study to be smartphone users likely skewed the
population to younger MI patients more likely to be
early adopters of innovative technology. Although older
generations have been slower in adopting new technol-
ogy, the N55-year-olds are predicted to be the age group
experiencing the fastest year-on-year rises in smartphone
uptake.31Conclusion
In MI patients, the use of a smartphone-based
interactive patient support tool improved patient
self-reported drug adherence and may be associated
with a trend toward improved CV lifestyle changes and
QoL. This disease-specific patient interactive support tool
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Volume 178(a smartphone app) appears to be an appreciated,
easy-to-use, and promising aid to improve drug adherence
and secondary prevention.Contributions
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